Tanzisertib(CC-930)

Catalog No.S8490 Batch:S849001

Print

Technical Data

Formula

C21H23F3N6O2.HCl

Molecular Weight 484.9 CAS No. 899805-25-5(freebase)
Solubility (25°C)* In vitro DMSO 89 mg/mL (183.54 mM)
Ethanol 89 mg/mL (183.54 mM)
Water 4 mg/mL (8.24 mM)
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
0.55mg/ml Taking the 1 mL working solution as an example, add 50 μL of 11 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.4mg/ml Taking the 1 mL working solution as an example, add 50 μL of 88 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tanzisertib (CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
Targets
JNK3 [1]
(Cell-free assay)
JNK2 [1]
(Cell-free assay)
JNK1 [1]
(Cell-free assay)
0.006 μM 0.007 μM 0.061 μM
In vitro CC-930 inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50 = 1 μM). CC-930 shows remarkable selectivity in a panel of 240 kinases, EGFR being the only non-MAP kinase inhibited more than 50% at 3 μM (IC50 = 0.38 μM). It inhibits no receptor at greater than 50% at 10 μM concentration in a panel of 75 receptors, ion channels and neurotransmitter transporters. CC-930 does not inhibit CYP P450 enzymes significantly and is metabolized by CYP 3A4 and 2D6[1].
In vivo In the acute rat LPS-induced TNFα production PK-PD model, the compound inhibits the production of TNFα by 23% and 77% at 10 and 30 mg/kg oral dose respectively. CC-930 is well-tolerated and exposure is dose-proportional[1].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    Jurkat T cells

  • Concentrations

    --

  • Incubation Time

    30 minutes

  • Method

    Jurkat T cells (5×105 /well) are aliquoted in 96 well membrane filter plates, then treated with or without compound 30 minutes prior to stimulation with 0.3 μg/ml anisomycin for an additional 40 minutes. Cells are pelleted under vacuum with plate manifold. Cell lysates are prepared by adding 75 μl/well lysis buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 0.2% Triton X-100, 0.5 mM DTT, 2x phosphatase inhibitors, 20 mM PNPP, 1x protease inhibitors), for 30 minutes at room temperature. Lysates are filtered and collected into a new 96 well plate placed beneath the vacuum manifold. Cell lysates (45 μl) are added to an assay plate containing bound GST-c-Jun and MgCl2 in solution (10 mM) then incubated for 10 minutes at room temperature. The reaction is stopped by washing with Tris-buffered saline containing 0.02% Tween 20 and the phosphorylated GST-c-Jun detected by Europium labeled anti-phospho-c-Jun, DELFIA assay buffer and enhancement solution. Plate fluorescence is measured.

Animal Study:[1]
  • Animal Models

    Male C57Bl/6 mice

  • Dosages

    2 mg/kg(i.v.) or 10 mg/kg(p.o.)

  • Administration

    i.v. or p.o.

Selleck's Tanzisertib(CC-930) has been cited by 8 publications

Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice [ Signal Transduct Target Ther, 2023, 8(1):94] PubMed: 36864030
A Chemical Proteomics Approach to Discover Regulators of Innate Immune Signaling [ Viruses, 2023, 15(5)1112] PubMed: 37243198
Alternative splicing of apoptosis genes promotes human T cell survival [ Elife, 2022, 11e80953] PubMed: 36264057
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] PubMed: 32645325
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] PubMed: 32645325
PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer. [ Int J Cancer, 2020, 146(9):2563-2575] PubMed: 31498891
Targeting JNK pathway promotes human hematopoietic stem cell expansion. [ Cell Discov, 2019, 5:2] PubMed: 30622738
Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner [ J Cell Mol Med, 2019, 23(2):920-933] PubMed: 30394679

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.